Back to Search
Start Over
First Line Therapy Evaluation Using Propensity Score Approach in Newly Diagnosed Advanced Classical Hodgkin Lymphoma Patients from Prospective Real-World Realysa Cohort and Phase 3 AHL2011 Trial
- Source :
- Blood; November 2023, Vol. 142 Issue: 1, Number 1 Supplement 1 p3056-3056, 1p
- Publication Year :
- 2023
-
Abstract
- Background: AHL2011, a randomized phase III trial demonstrated that PET-CT after two cycles of BEACOPP escalatedchemotherapy safely guided treatment of patients aged 16-60 years with newly diagnosed advanced classical Hodgkin lymphoma (cHL) and allowed the use of ABVD in early responders with reduced toxicities and no impaired disease control. REALYSA study, a real-life multicentric cohort set up in France since 2018, included 6000 newly diagnosed lymphoma patients with over 1000 cHL patients. In the present study, we investigated whether real-world data could reproduce results issued from a randomized phase III clinical trial using the propensity score approach.
Details
- Language :
- English
- ISSN :
- 00064971 and 15280020
- Volume :
- 142
- Issue :
- 1, Number 1 Supplement 1
- Database :
- Supplemental Index
- Journal :
- Blood
- Publication Type :
- Periodical
- Accession number :
- ejs64701070
- Full Text :
- https://doi.org/10.1182/blood-2023-178154